Nash Treatment

Prof. Sven Francque

Why are PPAR agonists a promising option for the management of NASH ?

Prof. Sven Francque, Chair of the PanNASH initiative reviews the current management options in NASH and the many molecules in development. It sheds light on the rationale for PPAR agonists as a promising and very valuable therapeutic option with systemic potential, for what happens in the liver and outside of the liver.
View More ⏩Why are PPAR agonists a promising option for the management of NASH ?

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES